Novelion Therapeutics (TSX:NVLN) Current Deferred Taxes Liabilities : C$0.0 Mil (As of Mar. 2019)

View and export this data going back to 1988. Start your Free Trial

What is Novelion Therapeutics Current Deferred Taxes Liabilities?

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

Novelion Therapeutics's current deferred tax liabilities for the quarter that ended in Mar. 2019 was C$0.0 Mil.

Novelion Therapeutics Current Deferred Taxes Liabilities Historical Data

The historical data trend for Novelion Therapeutics's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novelion Therapeutics Current Deferred Taxes Liabilities Chart

Novelion Therapeutics Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Current Deferred Taxes Liabilities

Get a 7-Day Free Trial

Novelion Therapeutics Quarterly Data
	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19
Current Deferred Taxes Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Novelion Therapeutics Current Deferred Taxes Liabilities Related Terms

Thank you for viewing the detailed overview of Novelion Therapeutics's Current Deferred Taxes Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Novelion Therapeutics (TSX:NVLN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novelion Therapeutics Inc (TSX:NVLN) » Definitions » Current Deferred Taxes Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

c/o Norton Rose Fulbright, 1800 West Georgia Street, Suite 510, Vancouver, BC, CAN, V6B 0M3

Website

http://www.novelion.com

Headquartered in Vancouver, Canada, QLT is a biotechnology company that researches and develops products used to treat conditions of the eye. After a recent board change, QLT divested its only marketed product, a laser treatment called Visudyne for the treatment of wet age-related macular degeneration and subfoveal choroidal neovascularization. QLT also earns royalty payments on other certain previously divested products. Following recent pipeline changes, the company currently has one product in development for two rare eye conditions.

Novelion Therapeutics (TSX:NVLN) Headlines

No Headlines